Cardiovascular Agents

Document Type

Article

Publication Date

10-2010

Abstract

With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications. This is particularly true in patients on chronic hemodialysis. Approximately 30% of medication-related prob lems in ambulatory hemodialy- sis patients occurred with agents used to treat cardiovas- cular disease (1). These findings were reinforced in another study that showed that 60% of cardiovascular medications were inappropr iately dosed or contraindi- cated in hospitalized patients with CKD (2). This article will review some of the most common drug use errors seen in our hemodialysis population .

Publication Title

Seminars in Dialysis

Volume

23

Issue

5

First Page

480

Last Page

482

Comments

This article was published in Seminars in Dialysis, Volume 23, Issue 5, October 2010, pages 480-482.

The published version is available at http://dx.doi.org/10.1111/j.1525-139X.2010.00778.x

Copyrigh © 2010 Wiley.

This document is currently not available here.

COinS